收费全文 | 3357篇 |
免费 | 205篇 |
国内免费 | 43篇 |
耳鼻咽喉 | 58篇 |
儿科学 | 76篇 |
妇产科学 | 77篇 |
基础医学 | 347篇 |
口腔科学 | 70篇 |
临床医学 | 245篇 |
内科学 | 1079篇 |
皮肤病学 | 20篇 |
神经病学 | 312篇 |
特种医学 | 110篇 |
外科学 | 586篇 |
综合类 | 7篇 |
预防医学 | 68篇 |
眼科学 | 25篇 |
药学 | 170篇 |
中国医学 | 21篇 |
肿瘤学 | 334篇 |
2023年 | 19篇 |
2022年 | 17篇 |
2021年 | 92篇 |
2020年 | 40篇 |
2019年 | 56篇 |
2018年 | 95篇 |
2017年 | 70篇 |
2016年 | 81篇 |
2015年 | 103篇 |
2014年 | 114篇 |
2013年 | 152篇 |
2012年 | 248篇 |
2011年 | 242篇 |
2010年 | 140篇 |
2009年 | 121篇 |
2008年 | 196篇 |
2007年 | 236篇 |
2006年 | 228篇 |
2005年 | 221篇 |
2004年 | 217篇 |
2003年 | 216篇 |
2002年 | 236篇 |
2001年 | 38篇 |
2000年 | 38篇 |
1999年 | 24篇 |
1998年 | 50篇 |
1997年 | 43篇 |
1996年 | 36篇 |
1995年 | 44篇 |
1994年 | 20篇 |
1993年 | 27篇 |
1992年 | 19篇 |
1991年 | 20篇 |
1990年 | 9篇 |
1989年 | 8篇 |
1988年 | 8篇 |
1987年 | 7篇 |
1986年 | 7篇 |
1985年 | 13篇 |
1984年 | 10篇 |
1983年 | 4篇 |
1982年 | 4篇 |
1981年 | 4篇 |
1980年 | 7篇 |
1979年 | 2篇 |
1978年 | 5篇 |
1977年 | 4篇 |
1976年 | 3篇 |
1975年 | 3篇 |
1969年 | 2篇 |
Osimertinib is effective in patients with T790M mutation-positive advanced non-small-cell lung cancer (NSCLC) resistant to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs). However, its effectiveness and safety in patients with poor performance status (PS) are unknown.
MethodsEnrolled patients showed disease progression after treatment with gefitinib, erlotinib, or afatinib; T790M mutation; stage IIIB, IV, or recurrent disease; and PS of 2–4. Osimertinib was orally administered at a dose of 80 mg/day. The primary endpoint of this phase II study (registration, jRCTs061180018) was response rate and the secondary endpoints were progression-free survival (PFS), overall survival (OS), disease control rate, and safety.
ResultsThirty-three patients were enrolled, of which 69.7% and 24.2% had PS of 2 and 3, respectively. One patient was excluded due to protocol violation; in the remaining 32 patients, the response rate was 53.1%; disease control rate was 75.0%; PFS was 5.1 months; and OS was 10.0 months. The most frequent adverse event of grade 3 or higher severity was lymphopenia (12.1%). Interstitial lung disease (ILD) was observed at all grades and at grades 3–5 in 15.2% (5/33) and 6.1% (2/33) of patients, respectively. Treatment-related death due to ILD occurred in one patient. Patients negative for activating EGFR mutations after osimertinib administration had longer median PFS than those positive for these mutations.
ConclusionOsimertinib was sufficiently effective in EGFR-TKI-resistant, poor PS patients with T790M mutation-positive advanced NSCLC. Plasma EGFR mutation clearance after TKI treatment could predict the response to EGFR-TKIs.
相似文献Methods: Four-dimensional (4D) ultrasound was used to examine the facial expressions of 50 AGA, 25 SGA, and six FGR fetuses between 28 and 35 weeks of gestation. The frequencies of seven facial expressions during 15-minute recordings were assessed. Comparison of facial expressions among the three groups was performed.
Results: Mouthing was the commonest facial expression at 28–35 weeks, and the frequency of mouthing was significantly higher than those of the other six facial expressions in AGA fetuses. Mouthing was the most frequent facial expression, but there was no significant difference in the frequency among mouthing, smiling and blinking in SGA fetuses. Moreover, mouthing displayed a significantly higher frequency than the other facial expressions, except for yawning, smiling, and blinking in FGR fetuses. However, there was no significant difference in the frequency of each facial expression among the three groups.
Conclusions: Our results suggest that the frequencies of fetal facial expressions are not decreased in either SGA or FGR pregnancies. The absence of a decrease in the frequency of each fetal expression in FGR fetuses may be due to increased brain blood flow because of the brain-sparing effect. Moreover, accelerated maturation and development of the brain function, especially the central dopamine system, might be suspected in SGA and FGR fetuses. 相似文献